Cargando…
Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an ant...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709080/ https://www.ncbi.nlm.nih.gov/pubmed/23812247 http://dx.doi.org/10.1007/s00395-013-0366-9 |
_version_ | 1782276701528522752 |
---|---|
author | Haghikia, A. Podewski, E. Libhaber, E. Labidi, S. Fischer, D. Roentgen, P. Tsikas, D. Jordan, J. Lichtinghagen, R. von Kaisenberg, C. S. Struman, I. Bovy, N. Sliwa, K. Bauersachs, J. Hilfiker-Kleiner, Denise |
author_facet | Haghikia, A. Podewski, E. Libhaber, E. Labidi, S. Fischer, D. Roentgen, P. Tsikas, D. Jordan, J. Lichtinghagen, R. von Kaisenberg, C. S. Struman, I. Bovy, N. Sliwa, K. Bauersachs, J. Hilfiker-Kleiner, Denise |
author_sort | Haghikia, A. |
collection | PubMed |
description | Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an anti-angiogenic 16 kDa subfragment emerged as a potential causal factor of the disease. We established a prospective registry with confirmed PPCM present in 115 patients (mean baseline left ventricular ejection fraction, LVEF: 27 ± 9 %). Follow-up data (6 ± 3 months) showed LVEF improvement in 85 % and full recovery in 47 % while 15 % failed to recover with death in 2 % of patients. A positive family history of cardiomyopathy was present in 16.5 %. Pregnancy-associated hypertension was associated with a better outcome while a baseline LVEF ≤ 25 % was associated with a worse outcome. A high recovery rate (96 %) was observed in patients obtaining combination therapy with beta-blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor-blockers (ARBs) and bromocriptine. Increased serum levels of Cathepsin D, the enzyme that generates 16 kDa Prolactin, miR-146a, a direct target of 16 kDa Prolactin, N-terminal-pro-brain-natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) emerged as biomarkers for PPCM. In conclusion, low baseline LVEF is a predictor for poor outcome while pregnancy-induced hypertensive disorders are associated with a better outcome in this European PPCM cohort. The high recovery rate in this collective is associated with a treatment concept using beta-blockers, ACE inhibitors/ARBs and bromocriptine. Increased levels of Cathepsin D activity, miR-146a and ADMA in serum of PPCM patients support the pathophysiological role of 16 kDa Prolactin for PPCM and may be used as a specific diagnostic marker profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-013-0366-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-3709080 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-37090802013-07-15 Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy Haghikia, A. Podewski, E. Libhaber, E. Labidi, S. Fischer, D. Roentgen, P. Tsikas, D. Jordan, J. Lichtinghagen, R. von Kaisenberg, C. S. Struman, I. Bovy, N. Sliwa, K. Bauersachs, J. Hilfiker-Kleiner, Denise Basic Res Cardiol Original Contribution Peripartum cardiomyopathy (PPCM) is a life-threatening heart disease developing towards the end of pregnancy or in the months following delivery in previously healthy women in terms of cardiac disease. Enhanced oxidative stress and the subsequent cleavage of the nursing hormone Prolactin into an anti-angiogenic 16 kDa subfragment emerged as a potential causal factor of the disease. We established a prospective registry with confirmed PPCM present in 115 patients (mean baseline left ventricular ejection fraction, LVEF: 27 ± 9 %). Follow-up data (6 ± 3 months) showed LVEF improvement in 85 % and full recovery in 47 % while 15 % failed to recover with death in 2 % of patients. A positive family history of cardiomyopathy was present in 16.5 %. Pregnancy-associated hypertension was associated with a better outcome while a baseline LVEF ≤ 25 % was associated with a worse outcome. A high recovery rate (96 %) was observed in patients obtaining combination therapy with beta-blocker, angiotensin-converting enzyme (ACE) inhibitors/angiotensin-receptor-blockers (ARBs) and bromocriptine. Increased serum levels of Cathepsin D, the enzyme that generates 16 kDa Prolactin, miR-146a, a direct target of 16 kDa Prolactin, N-terminal-pro-brain-natriuretic peptide (NT-proBNP) and asymmetric dimethylarginine (ADMA) emerged as biomarkers for PPCM. In conclusion, low baseline LVEF is a predictor for poor outcome while pregnancy-induced hypertensive disorders are associated with a better outcome in this European PPCM cohort. The high recovery rate in this collective is associated with a treatment concept using beta-blockers, ACE inhibitors/ARBs and bromocriptine. Increased levels of Cathepsin D activity, miR-146a and ADMA in serum of PPCM patients support the pathophysiological role of 16 kDa Prolactin for PPCM and may be used as a specific diagnostic marker profile. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00395-013-0366-9) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2013-06-28 2013 /pmc/articles/PMC3709080/ /pubmed/23812247 http://dx.doi.org/10.1007/s00395-013-0366-9 Text en © The Author(s) 2013 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Contribution Haghikia, A. Podewski, E. Libhaber, E. Labidi, S. Fischer, D. Roentgen, P. Tsikas, D. Jordan, J. Lichtinghagen, R. von Kaisenberg, C. S. Struman, I. Bovy, N. Sliwa, K. Bauersachs, J. Hilfiker-Kleiner, Denise Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title | Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title_full | Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title_fullStr | Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title_full_unstemmed | Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title_short | Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy |
title_sort | phenotyping and outcome on contemporary management in a german cohort of patients with peripartum cardiomyopathy |
topic | Original Contribution |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709080/ https://www.ncbi.nlm.nih.gov/pubmed/23812247 http://dx.doi.org/10.1007/s00395-013-0366-9 |
work_keys_str_mv | AT haghikiaa phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT podewskie phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT libhabere phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT labidis phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT fischerd phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT roentgenp phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT tsikasd phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT jordanj phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT lichtinghagenr phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT vonkaisenbergcs phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT strumani phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT bovyn phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT sliwak phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT bauersachsj phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy AT hilfikerkleinerdenise phenotypingandoutcomeoncontemporarymanagementinagermancohortofpatientswithperipartumcardiomyopathy |